東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Learnings on Immunosenescence from t...

Davies-Abraham, Merlin,

FindBook

Google Book

Amazon

博客來

Learnings on Immunosenescence from the COVID-19 Pandemic /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Learnings on Immunosenescence from the COVID-19 Pandemic // Merlin Davies-Abraham.
作者:	Davies-Abraham, Merlin,
面頁冊數:	1 electronic resource (281 pages)
附註:	Source: Dissertations Abstracts International, Volume: 86-05, Section: A.
Contained By:	Dissertations Abstracts International86-05A.
標題:	Lymphocytes. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31744542
ISBN:	9798346587088

Learnings on Immunosenescence from the COVID-19 Pandemic /
Davies-Abraham, Merlin,

Learnings on Immunosenescence from the COVID-19 Pandemic /Merlin Davies-Abraham. - 1 electronic resource (281 pages)

Source: Dissertations Abstracts International, Volume: 86-05, Section: A.

Background Age related diseases represent a major concern within the global population due to an increasing proportion of older to younger adults. With ageing, individuals experience a decline in their immunological function, which leads to a reduced ability to respond to viral infections and vaccinations, such as SARS-CoV-2. Age-related senescent immune cells have been well characterised in the adaptive immune repertoire, however, the impact of immunosenescence on response to viral infection is less known - particularly in context of the COVID-19 pandemic. This thesis aims to understand the degree to which age and senescence is associated with poor viral response and clearance, whilst also providing pilot understanding for the impact that T2D plays in exacerbating an immunosenescent phenotype. Senotherapeutic drugs have effectively ameliorated senescence in various cell and tissue types. As such, they represent a novel drug development opportunity for ageing immunity, which is piloted here too. Methods Data chapter 3 of this thesis involved collection of PBMC blood sampling from a cohort of 49 individuals, split into groups of 18-35 years old and 60+ years old. PBMCs were evaluated for T cell senescence using flow cytometry, RT-qPCR, microsatellite sequencing and ELISAs. Data chapter 4 studied a cohort of 265 SARS-CoV-2 positive individuals, where RNA was tested using RT-qPCR assays for sub-genomic RNA - an element of active SARS-CoV-2 infections to understand viral load dynamics. Data chapter 5 is a pilot study which assesses the impact of senotherapeutic intervention on the antibody production, senescence markers and TCR clonality in older PBMCs both with and without the presence of SARS-CoV-2spike protein. These are assessed using RT-qPCR, microsatellite sequencing and ELISAs.ResultsI identified that aged individuals demonstrated higher immune ageing metrics from flow cytometry relative to younger counterparts (Median respective IMMAX scores: 0.75 vs 0.48, P<0.0001). This correlated with IgG production in individuals reporting a COVID infection within 6 months of sampling, where lower scores correlated with improved antibody response (p=0.048). This is further linked to higher immune age metrics correlated to reduced TCR delta diversity both without and with spike treatment (p<0.0001 and p=0.0001 respectively).Whilst no associations were found between viral load and age, higher viral loads were associated with worsened COVID-19 outcomes using existing and novel sgRNA targeted testing for infectious virus (p=0.006 and p=0.03 respectively). This data also demonstrated that individuals can remain infectious beyond 10 days, without predictive clinical characteristics.Average IgG production in trametinib treated cells is 21.7 ng/mL higher within older adult samples when treated with SARS-CoV-2 Omicron spike protein (p<0.0001), however may largely be due to and adjuvant effect of trametinib. Evaluation of typical molecular markers of senescence demonstrated younger and older adult spike challenged PBMCs have statistically significant differences in P53, P21 and P16 markers of senescence when metabolically challenge (p=0.0008/p=0.0009/p=0.0107 respectively). Conclusions This thesis contributes to knowledge of SARS-CoV-2 viral kinetics. Work here also assesses mechanisms for how immunosenescence causes declining immune function in older adults and individuals with metabolic disease. Finally, pilot data evaluates the potential for senotherapeutic drug interventions as a method of vaccine adjuvant and improvement of ageing immunity.

English

ISBN: 9798346587088Subjects--Topical Terms:

895384
Lymphocytes.

Learnings on Immunosenescence from the COVID-19 Pandemic /
LDR:04888nmm a22004093i 4500 001 2430832
005 20250603111626.5
006 m o d
007 cr|nu||||||||
008 261011s2023 miu||||||m |||||||eng d
020 $a 9798346587088
035 $a (MiAaPQD)AAI31744542
035 $a (MiAaPQD)Exeter10871137734
035 $a AAI31744542
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Davies-Abraham, Merlin, $e author. $3 3819348
245 1 0 $a Learnings on Immunosenescence from the COVID-19 Pandemic / $c Merlin Davies-Abraham.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2023
300 $a 1 electronic resource (281 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-05, Section: A.
500 $a Advisors: Harries, Lorna.
502 $b Ph.D. $c University of Exeter (United Kingdom) $d 2023.
520 $a Background Age related diseases represent a major concern within the global population due to an increasing proportion of older to younger adults. With ageing, individuals experience a decline in their immunological function, which leads to a reduced ability to respond to viral infections and vaccinations, such as SARS-CoV-2. Age-related senescent immune cells have been well characterised in the adaptive immune repertoire, however, the impact of immunosenescence on response to viral infection is less known - particularly in context of the COVID-19 pandemic. This thesis aims to understand the degree to which age and senescence is associated with poor viral response and clearance, whilst also providing pilot understanding for the impact that T2D plays in exacerbating an immunosenescent phenotype. Senotherapeutic drugs have effectively ameliorated senescence in various cell and tissue types. As such, they represent a novel drug development opportunity for ageing immunity, which is piloted here too. Methods Data chapter 3 of this thesis involved collection of PBMC blood sampling from a cohort of 49 individuals, split into groups of 18-35 years old and 60+ years old. PBMCs were evaluated for T cell senescence using flow cytometry, RT-qPCR, microsatellite sequencing and ELISAs. Data chapter 4 studied a cohort of 265 SARS-CoV-2 positive individuals, where RNA was tested using RT-qPCR assays for sub-genomic RNA - an element of active SARS-CoV-2 infections to understand viral load dynamics. Data chapter 5 is a pilot study which assesses the impact of senotherapeutic intervention on the antibody production, senescence markers and TCR clonality in older PBMCs both with and without the presence of SARS-CoV-2spike protein. These are assessed using RT-qPCR, microsatellite sequencing and ELISAs.ResultsI identified that aged individuals demonstrated higher immune ageing metrics from flow cytometry relative to younger counterparts (Median respective IMMAX scores: 0.75 vs 0.48, P<0.0001). This correlated with IgG production in individuals reporting a COVID infection within 6 months of sampling, where lower scores correlated with improved antibody response (p=0.048). This is further linked to higher immune age metrics correlated to reduced TCR delta diversity both without and with spike treatment (p<0.0001 and p=0.0001 respectively).Whilst no associations were found between viral load and age, higher viral loads were associated with worsened COVID-19 outcomes using existing and novel sgRNA targeted testing for infectious virus (p=0.006 and p=0.03 respectively). This data also demonstrated that individuals can remain infectious beyond 10 days, without predictive clinical characteristics.Average IgG production in trametinib treated cells is 21.7 ng/mL higher within older adult samples when treated with SARS-CoV-2 Omicron spike protein (p<0.0001), however may largely be due to and adjuvant effect of trametinib. Evaluation of typical molecular markers of senescence demonstrated younger and older adult spike challenged PBMCs have statistically significant differences in P53, P21 and P16 markers of senescence when metabolically challenge (p=0.0008/p=0.0009/p=0.0107 respectively). Conclusions This thesis contributes to knowledge of SARS-CoV-2 viral kinetics. Work here also assesses mechanisms for how immunosenescence causes declining immune function in older adults and individuals with metabolic disease. Finally, pilot data evaluates the potential for senotherapeutic drug interventions as a method of vaccine adjuvant and improvement of ageing immunity.
546 $a English
590 $a School code: 5016
650 4 $a Lymphocytes. $3 895384
650 4 $a DNA methylation. $3 3560639
650 4 $a Epigenetics. $3 1568224
650 4 $a Older people. $3 761975
650 4 $a Viral infections. $3 3540521
650 4 $a Aging. $3 543123
650 4 $a Biochemistry. $3 518028
650 4 $a Genetics. $3 530508
650 4 $a Gerontology. $3 533633
650 4 $a Virology. $3 642304
690 $a 0493
690 $a 0487
690 $a 0369
690 $a 0351
690 $a 0720
710 2 $a University of Exeter (United Kingdom). $e degree granting institution. $3 3767447
720 1 $a Harries, Lorna $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-05A.
790 $a 5016
791 $a Ph.D.
792 $a 2023
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31744542